Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section
 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Principal Investigator (?)
Study Number
F18083
Summary
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older. Approximately 415 subjects will be enrolled in this study at about 100 sites in North America, Europe, and Australia. The planned duration of treatment with study drug is 28 weeks. Study drug will be lenabasum 20 mg BID, lenabasum 5 mg BID, and placebo in a 2:1:2 ratio. 
Phase (?)
Phase III
Sponsor (?)
Contact

Dana Dorman

Available at the following location(s)

Manchester

View more details from ClinicalTrials.gov.

0